Kornimate/medical-research-clean huggingface dataset:
cd4 in combination with chop in treating non-cutaneous peripheral tcell lymphoma

Conditions: T-cell Lymphoma

Summary: evaluation of cd4 in combination with cho chemotherapy in subjects with nodal involvement of non cutaneous tcell lymphoma.


Eligibility criteria:
inclusion criteria: * study is closed to enrollment exclusion criteria: * study is closed to enrollment

Keywords: non cutaneous peripheral t-cell lymphoma with nodal involvement
european carto® xp registry for validating specialized cfae software

Conditions: Atrial Fibrillation

Summary: the purpose of this prospective observational study (registry) is to determine the acute success rate of a complex fractionated atrial electrogram (cfae) guided ablation procedure using a dedicated software and to determine the functionality and performance of the cfae software in patients with a type of persistent atrial fibrillation (af) in routine clinical practice.

this was a prospective, multi-center, observational registry study evaluating carto® xp cfae software (cfae software) in subjects with chronic af requiring cfae-guided rfca. use of the carto® 3 system (including cfae software) was also allowed. the primary efficacy endpoint was the acute success rate of cfae-guided radiofrequency catheter ablation (rfca) using the cfae software. acute success is defined as the subject achieving sinus rhythm at the end of the procedure without electrical or pharmaceutical cardioversion. secondary endpoints consisted of measures of efficacy (example, performance of the cfae software) and of safety (example, number of procedure-related adverse events).

Eligibility criteria:
inclusion criteria: * persistent or longstanding persistent af exclusion criteria: * previously underwent rf ablation for af and patients with paroxysmal af

Keywords: persistent or longstanding persistent atrial fibrillation
addiction remission and addiction transfer after bariatric surgery

Conditions: Obesity

Summary: to evaluate addiction remission and addiction transfer after bariatric surgery.

a prospective study to evaluate addiction remission and addiction transfer 6 and 24 months after primary surgery (sleeve gastrectomy, roux-en-y- gastric bypass and one anastomosis gastric bypass) in obese patients. a questionnaire evaluating food addiction (yale food scale), alcohol addiction (audit scale), nicotine addiction (fagerström scale), exercise addiction (exercise addiction inventory), internet addiction (iss20) and drug addiction (drug use questionnaire) gets completed prior to surgery and 6 and 24 months after surgery.

Eligibility criteria:
inclusion criteria: * bmi \> 35kg/m² and obesity related disease or bmi \> 40kg/m² exclusion criteria: * decline of study participation

Keywords: addiction remission addiction transfer
efficacy of intralesional prp in treatment of onychomycosis

Conditions: Platelet Rich Plasma

Summary: this study aims to investigate efficacy of intralesional prp in treatment of finer nail onychomycosis.

onychomycosis is a challenging medical condition with limited response to oral antifungal drugs. recent study demonstrated that platelet rich plasma (prp) have immuno-enhancing and antimicrobial properties. it had been shown that platelet microbicidal proteins released after platelet activation demonstrate potent activities against many gram-negative, gram-positive, and fungal pathogens in vitro and in vivo studies. in addition, white blood cell concentration in prp was reported to be two to fourfold their normal level in whole blood. neutrophils release myeloperoxidase which has a defensive action against fungi and bacteria, while lymphocytes and monocytes both are immunogenic cells (badade et al., 2016). recently, prp was successfully used in the treatment of multiple recalcitrant plane warts (abu el-hamd et al., 2021), also, prp proved its efficacy in inhibiting periodontal pathogens such as p. gingivalis and a. actinomycetemcomitans (badade et al., 2016). in addition, relevance of platelets for antifungal defenses might be suggested by the fact that thrombocytopenia represents a highly significant risk factor for fungal infections in post-transplant liver patients (chang et al., 2000). this study compares between intralesional rpr versus oral antifungal versus intralesional prp + oral antifungal in the treatment of finger nail onychmycosis.

Eligibility criteria:
inclusion criteria: * eligible participants will be adult patients (\> 18 years) with onychomycosis confirmed by dermoscopy, direct koh microscopic examination and positive culture.. exclusion criteria: * patients with one or more with the following criteria will be excluded. 1. pregnant and lactating women. 2. patients received topical and/or systemic antifungal therapy during the previous 3 months. 3. patients with impaired liver or renal functions. 4. patients with anemia (hemoglobin level \<10mg/dl), thrombocytopenia (platelet count \< 100,000 /µl), coagulopathies or patients on anticoagulant therapy as aspirin and patients with iron deficiency.

Keywords: prp, platelet rich plasma, terbinafine, onychomycosis
generic testing of antigen tests for covid-19 in denmark

Conditions: SARS-CoV2 Infection; COVID-19 Testing

Summary: to evaluate the analytical and clinical sensitivity and specificity of antigen tests performed as oropharyngeal swabs, outer nasal swabs, saliva swabs or breath tests including self-tests for sars-cov-2 towards standard rt-pcr testing. for each test 200 sars-cov-2 positive and 200 sars-cov-2 negative individuals previously defined by rt-pcr are tested. when tested an additional rt-pcr test is performed to verify status. analytical sensitivity and specificity is determined on 210 sars-cov-2 positive samples with known cq and 100 sars-cov-2 negative samples. 30 companies with a total of 55 tests participate in this nationwide study.


Eligibility criteria:
inclusion criteria: * age 18 years or over, * capacity to give informed, written consent * be able to cooperate to the additional testing. exclusion criteria: * individuals not fulfilling the inclusion criteria * declining additional oropharyngeal, nasal or saliva swabs.

Keywords: antigen test rt-pcr prospective samples retrospective samples
circulating cell-free dna as a predictive biomarker for hepatocelluar carcinoma.

Conditions: Hepatocellular Carcinoma

Summary: circulating free cell dna (cfdna) is extracellular fragmentation of nucleic acids that occurs both in plasma and serum. this kind of dna which derived from the apoptotic/necrotic cells or the lysis of circulating tumor cells (ctcs) can be detectedin the patients with a variety of diseases. emerging evidence suggests that cfdna from patients exhibits characteristicchanges of tumors, suchas mutations, insertions/deletions, methylations,microsatellite aberrations, and copy number variations, etc. all of these reveal a visible difference between the benign conditions, and thus may be useful in the diagnosis of cancer, identification of targeted therapy, monitor responses to treatments, and early detection of relapse. the purpose for this study is to explore these characteristic changes in the patients withhepatocellular carcinoma (hcc) and expect to guide targeted therapy and identify non-invasive biomarkers of cancer diagnosis and prognosis which can be easily isolated from the circulation.

in cancer, cfdna can be detected a higher concentration in the circulation because of the necrosis of neoplasm cells with the rapid enlargement and relatively shortage of blood supply. so, identifying tumor-specific genetic and epigenetic changes in cfdna on this status, such as gene mutations, deletions, methylation alterations and microsatellite alterations, may be more specific for us to diagnose the neoplasms in early phase. this phenomenon also appears in the patients with hepatocellular carcinoma (hcc). studies have shown that cfdna level is associated with intrahepatic and extrahepatic metastasis in hcc patients and examined some cfdnacharacteristic changes, such as p161nk4a, rtl, rassf1a, line-1 and gstp1. thus is useful for us to explore the specific cfdna in hcc. for a high sensitivity and specificity detection, we will use technologiesdeveloped at stanford genome technology centerto find more characteristic gene mutations, methylation alterations or other changes (3). in this study, we willinvestigate thesecharacteristic changesin cfdna and primary tumor lesions. study arrangement: collect the dna samples from the plasma, blood cells and solid tumor tissues in the patients with hcc. detect the dna sequence from the samples of plasma, blood cells and solid tumor tissues. identify cancer specific variations in cfdna and primary tumor lesions. date analysis and investigate these characteristic changes. evaluate the application in early diagnosis, treatment monitoring and prognosis for hcc.

Eligibility criteria:
inclusion criteria: age≥18years and ≤80 years; histologically and cytologically proven hepatocellular carcinoma child-pugh：child a-b adequate hematological, renal, cardiac and pulmonary functions tumor in any segment of liver exclusion criteria: uncontrolled systemic disease reject the surgical treatment metastatic carcinoma child-pugh：child c

Keywords: hepatocellular carcinoma；cell free tumor dna; mutation;
comparison of telbivudine versus lamivudine on the early dynamics and kinetics of viral suppression in chronic hepatitis b

Conditions: Hepatitis B, Chronic

Summary: this study examines the effect of telbivudine compared to lamivudine on the early viral kinetics in patients with chronic hepatitis b. the virus kinetics is measured by the viral load (hbv-dna) reduction in the serum during the first 12 weeks of therapy.


Eligibility criteria:
inclusion criteria: * documented compensated hbeag-positive or negative chronic hepatitis b * increased viral load with a concentration of serum hbv-dna of at least 10\^4 copies/ml * proof of inflammatory activity in the liver: alt ≥ 2 x uln or histological evidence of inflammatory activity ≥ level i or fibrosis of ≥ i degrees (according to the desmet classification) * negative urine pregnancy test with fertile women * willingness to use a recognized method of contraception * able to comply with study regimen and provide written informed consent exclusion criteria: * current or previous antiviral treatment of chronic hepatitis b with nucleus(t)id analoga * known hypersensitivity to lamivudine or telbivudine or any of the other components of the preparations * pregnant or breastfeeding women or women * simultaneous participation in other clinical trials or in the past three months * co-infected with hcv, hdv, hiv * other non hbv-related chronic liver disease: autoimmune hepatitis, primary biliary cirrhosis, hemochromatosis, alpha-1 antitrypsin deficiency, alcoholic hepatitis * evidence of hepatocellular carcinoma (alpha-fetoprotein levels\> 100 ng/ml) * active drug use, including an excessive alcohol consumption during the last 6 months before participating in the clinical trial * use of systemic treatment with anti-neoplastic or immunomodulatory medication within the last 6 months before participating in the clinical trial and during the duration of the clinical examination * lack of willingness or inability to consent in writing * concurrent condition likely to preclude compliance with schedule of evaluations

Keywords: viral kinetics viral dynamics telbivudine lamivudine
effects of whole-body electromyostimulation and dietary supplements on "sarcopenic obesity"

Conditions: Sarcopenic Obesity

Summary: the aim of the study is to determine the effect of whole body electromyostimulation (wb-ems) and/or nutritional on body composition and functional tasks in elderly females with sarcopenic obesity. seventy-five, non-sportive, independently living women 70 years and older with sarcopenic obesity were randomly assigned to either a wb-ems group ( n=25), a wb-ems/nutritional supplements (n=25) or a semi-active control group (an=25). the wb-ems protocol applied one session of 18 min/week of wb-ems (bipolar, 85 hz). nutritional strategy based on a high protein supplement.


Eligibility criteria:
inclusion criteria: * community dwelling * sarcopenic obesity exclusion criteria: * exercising more than 60 min/week * more than 4 weeks absent during the interventional period, * injuries (i.e. hip totalendoprosthesis (tep), abdomen/groin hernia) or diseases (i.e. epilepsy, cardiac arrhythmia) that prevent wb-ems intervention * medication and/or diseases affecting our primary endpoints.

Keywords: sarcopenic obesity community dwelling elderly women electromyostimulation exercise dietary supplements
pharyngeal anatomy in obstructive sleep apnea with hrm

Conditions: Obstructive Sleep Apnea

Summary: this is a single-arm study involving the use of a high resolution manometry (hrm) diagnostic device that is not utilized in any clinical decision-making processes. all patients scheduled for dise as part of their regular clinical care will be screened for enrollment via described inclusion and exclusion criteria.

high-resolution pharyngeal manometry (hrm) is a diagnostic technique that has the potential to objectively measure pharyngeal collapse patterns in obstructive sleep apnea (osa) during sedation as well as natural sleep. the purpose of this study is to assess the utility of hrm in objectively mapping patterns of pharyngeal collapse observed during drug-induced sleep endoscopy (dise). quantifying pharyngeal collapse patterns that occur during sedation and in natural sleep may significantly impact the selection and success of surgical treatments, as well as surgical outcome assessment.

Eligibility criteria:
inclusion criteria: * adult patient (≥18 years old) * a diagnosis of obstructive sleep apnea as determined by polysomnogram with an apnea-hypopnea index of ≥ 5.0/hr * intolerant of continuous positive airway pressure (cpap) therapy due to physical or psychosocial limitations as determined by pi * scheduled to undergo dise as part of routine clinical assessment for further evaluation of pharyngeal anatomy exclusion criteria: * patient is unable to consent for research due to a pre-existing neurologic condition as determined by pi * patient is unable to consent for research due to language barriers * patient has a history of egg allergy as determined by history or self- report * patient is pregnant as determined by patient report or preoperative anesthesia evaluation * cardiopulmonary or other medical conditions precluding safe sedation as determined by clinical history and exam * history of palatal or pharyngeal airway surgery except tonsillectomy as determined by clinical history and exam * history of radiation treatment to the head or neck as determined by clinical history and/or exam * severe nasal airway obstruction preventing simultaneous flexible nasopharyngoscopy and manometry probe insertion as determined by physical exam
obesity study to assess induction of labor

Conditions: Induction of Labor Affected Fetus / Newborn

Summary: there are more and more pregnant women who are obese. it is very difficult for obese women to get into labor. that is why when women are obese, half are likely to need a cesarean delivery(c-section). unfortunately, c-sections are more dangerous for obese women. there may be a combination of issues that cause obese women to need c-sections. we believe one of those reasons is that the womb of obese women respond differently to medications and devices compared to non-obese women. there are commonly two ways to help women get into labor. one way is a medication called misoprostol. the second way is a device called foley balloon. in most studies, both ways are equally effective in helping women get into labor. however, these studies included everyone, and didn't focus on obese women. so far there are no studies in this area that focus only on obese women. therefore we need to design this study to focus just on obese women and what is the best way to help them get into labor and avoid a c-section.


Eligibility criteria:
inclusion criteria: * morbidly obese patient (bmi≥40kg/m2) at admission for induction of labor speaks english gestational age between 37and0 weeks and 41and6 weeks cervical exam: dilation \<4cm and bishop score 6 or less contractions \< 2 per 10 minutes exclusion criteria: * history of cesarean delivery maternal contraindications to labor fetal contraindications to labor maternal age \<18yo fetal growth restriction with abnormal umbilical artery doppler indexes cervical dilation ≥4cm or bishop score ≥7 contractions ≥3 per 10 minutes non-reassuring fetal status latex allergy
etoposide plus cisplatin compared with temozolomide in patients with glioblastoma

Conditions: MGMT-Unmethylated Glioblastoma

Summary: temozolomide provided significant and clinically meaningful benefit in mgmt gene promoter methylation glioblastoma. however, in unmethylated patients, the effect of temozolomide is limited. the aim of this study is to compare the effect of etoposide plus cisplatin and temozolomide in patients with mgmt gene promoter unmethylation glioblastoma.

60 patients with glioblastoma were recruited for this study based on the following eligibility criteria: age between 18 and 70, performance status of 0-1 (eastern cooperative oncology group performance status), histologically confirmed mgmt gene promoter unmethylation glioblastoma, no cerebrospinal fluid and distant metastatic disease. all patients had adequate hematologic, hepatic, and renal function. patients younger than 18 years; patients with a prior (i.e. within 5 years) or synchronous malignancy, other than non-melanoma skin cancer; and those with significant comorbidities were excluded. 60 patients were randomly divided into two groups and compared the difference of efficacy between the two groups

Eligibility criteria:
inclusion criteria: * age between 18 and 70, * performance status of 0-1 (eastern cooperative oncology group performance status), * histologically confirmed mgmt gene promoter unmethylation glioblastoma * no cerebrospinal fluid and distant metastatic disease. * adequate hematologic, hepatic, and renal function exclusion criteria: * younger than 18 years; * with a prior (i.e. within 5 years) or synchronous malignancy, other than non-melanoma skin cancer; and those with significant comorbidities

Keywords: etoposide plus cisplatin temozolomide mgmt-unmethylated glioblastoma
effect of papillary epinephrine spraying for the prevention of post-ercp pancreatitis in patients received octreotide

Conditions: Post-ERCP Acute Pancreatitis; Epinephrine

Summary: post-endoscopic retrograde cholangiopancreatography (ercp) pancreatitis (pep) is the most common complication with high costs, significant morbidity and even mortality. the major mechanisms of pep is the papillary edema which is caused by manipulations during cannulation or endoscopic treatment. the papillary edema may cause temporary outflow obstruction of pancreatic juice, and then increase ductal pressure, resulting in the occurrence of pancreatitis. nitroglycerin can reduce the oddis sphincter tension, the internal pressure of the biliary tract and the pancreatic duct. therefore, it is widely used in clinical to prevent and treat pancreatitis. many studies found nitroglycerin might be effective in preventing pep. and topical application of epinephrine on the papilla may reduce papillary edema by decreasing capillary permeability or by relaxing the sphincter of oddi. there are reports that epinephrine sprayed on the papilla may be effective to prevent pep. the investigators therefore designed a prospective randomized trial to determine whether routine using papillary epinephrine spraying in patients received octreotide can reduce post-ercp pancreatitis.


Eligibility criteria:
inclusion criteria: 1. ercp surgery is required 2. signed inform consent form and agreed to follow-up on time. exclusion criteria: 1. acute pancreatitis. 2. pregnancy or history of allergy to epinephrine. 3. serious liver, kidney, heart and coagulation disorders 4. unwilling or inability to provide consent
an observational study of pegasys (peginterferon alfa-2a) and copegus (ribavirin) on predictive values of rvr on sustained virological response in different stages of liver fibrosis in treatment-naïve patients with chronic hepatitis c genotype 1

Conditions: Hepatitis C, Chronic

Summary: this observational study will evaluate the predictive value of rapid virological response (rvr) and early virological response (evr) on sustained virological response (svr) by stage of liver fibrosis in treatment-naïve patients with chronic hepatitis c genotype 1 initiated on treatment with pegasys (peginterferon alfa-2a) and copegus (ribavirin). patients will be followed for 48 weeks of treatment and up to 24 weeks of follow-up.


Eligibility criteria:
inclusion criteria: * adult patients, \>/= 18 years of age * chronic hepatitis c genotype 1 * treatment-naïve, i.e. have not been previously treated with pegylated interferon, standard interferon and ribavirin * confirmed serum positive hcv rna * liver fibrosis confirmed histologically or by fibroscan up to 24 months before treatment exclusion criteria: * any contraindications according to the summary of product characteristics for pegasys or copegus * co-infection with hepatitis b or hiv * post-transplant patients * end stage renal disease (creatinine clearance \< 15 ml/min) * patients treated with immunotherapy * pregnant women and male partners of women who are pregnant * female patients of childbearing potential and male patients with female partners of childbearing potential who are unable or unwilling to use effective and continuous contraception during the treatment and for 4 months (females) and 7 months (males) thereafter
changes in dynamic q angle in patients with chronic ankle instability

Conditions: Ankle Sprain Strain

Summary: this study investigates the difference in dynamic q-angle of patients with chronic ankle instability and those without.


Eligibility criteria:
inclusion criteria: * subjects aged between 18 and 30 years. * subjects with a history of las for at least one year before the study onset, that required at least 1-day weight-bearing restriction. * subjects with a self-reported tendency of ≥2 giving way episodes during 6 months before enrollment in the study. * subjects with a perception that the injured ankle was chronically weaker, more painful, and/or less functional than the contralateral ankle before the first las. * subjects who scored less than 24 in the cumberland ankle instability tool (cait), a validated ankle instability specific questionnaire of 9 items, to determine if functional ankle instability is present. exclusion criteria * subjects who had bilateral las * subjects with a history of lower extremity injury, fracture, or surgery * subjects who participated in supervised or unsupervised ankle rehabilitation within a year before enrollment in the study * subjects with las within 3 months before participation * subjects with a history of knee pain during the last 6 months. * subjects diagnosed with knee osteoarthritis.

Keywords: kinetic chain ankle instability q-angle